title: Lapatinib ditosylate GlaxoSmithKline.
abstract: Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.
authors.affiliation: 449 S Doheny Drive, Beverly Hills, CA 90211, USA. tracy.kim@snet.net
authors.forename: Tracy E
authors.initials: TE
authors.lastname: Kim
authors.forename: John R
authors.initials: JR
authors.lastname: Murren
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D005663:Furans / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011799:Quinazolines / Q000737:chemistry / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D005663:Furans; C470405:N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine; D011799:Quinazolines